News

05.01.21 Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace
16.12.20 Medannex chosen by Welp Magazine as a company to watch in the UK Clinical Trials space
17.08.20 Medannex completes final tranche of £11m Series B investment, led by Morningside Venture Capital
22.06.20 Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
15.06.20 Medannex announces Innovate UK grant award for novel cancer therapeutic development
10.03.20 Medannex announces new immunomodulatory approach to cancer treatment at Nature conference
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6